Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: A retrospective study;Hématomes maculaires après injections intravitréennes d'anti-VEGF pour dégénérescence maculaire liée à l'âge : série rétrospective

Journal Francais d'Ophtalmologie

Volumn 32, Issue 5, 2009, Pages 309-313

  Baeteman, C ^a,b   Hoffart, L ^a,b   Galland, F ^a,b   Ridings, B ^a,b   Conrath, J ^a,b  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITÉ   (France)

Author keywords

Age related macular degeneration; Intravitreal injection; Macular hemorrhages; VEGF

Indexed keywords

EID: 67349210607     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2009.04.001     Document Type: Article

References (23)

1. Fung A.E., Rosenfeld P.J., and Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 90 (2006) 1344-1349
2. Chieh J.J., and Fekrat S. Large subretinal hemorrhage after intravitreal bevacizumab (Avastin) for age-related macular degeneration. Ann Ophthalmol (Skokie) 39 (2007) 51-52
3. Wong L.J., Desai R.U., Jain A., Feliciano D., Moshfeghi D.M., Sanislo S.R., and Blumenkranz M.S. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease. Retina 28 (2008) 1151-1158
4. Goverdhan S.V., and Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol 92 (2008) 210-212
5. Huang G.C., Chen L.J., Liu H.C., and Chen Y.J. Development of Vitreous Haemorrhage during Treatment with Bevacizumab for Metastatic Rectal Cancer. Clin Drug Investig 28 (2008) 523-526
6. Shah C.P., Hsu J., Garg S.J., Fischer D.H., and Kaiser R. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Am J Ophthalmol 142 (2006) 1070-1072
7. Bakri S.J., and Kitzmann A.S. Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol. 143 (2007) 505-507
8. Chan C.K., and Lin S.G. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 17 (2007) 674-676
9. Lee G.K., Lai T.Y., Chan W.M., and Lam D.S. Retinal pigment epithelial tear following intravitreal ranibizumab injections for neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 245 (2007) 1225-1227
10. Nicolò M., Ghiglione D., and Calabria G. Retinal pigment epithelial tear following intravitreal injection of bevacizumab. Eur J Ophthalmol 16 (2006) 770-773
11. Chang L.K., Flaxel C.J., Lauer A.K., and Sarraf D. RPE tears after pegaptanib treatment in age-related macular degeneration. Retina 27 (2007) 857-863
12. Dhalla M.S., Blinder K.J., Tewari A., Hariprasad S.M., and Apte R.S. Retinal pigment epithelial tear following intravitreal pegaptanib sodium. Am J Ophthalmol 141 (2006) 752-754
13. Chan C.K., Meyer C.H., Gross J.G., Abraham P., Nuthi A.S., Kokame G.T., Lin S.G., Rauser M.E., and Kaiser P.K. Retinal pigment epithelial tears after intravitreal bevacizumab injection for neovascular age-related macular degeneration. Retina 27 (2007) 541-551
14. Gelisken F., Ziemssen F., Voelker M., Bartz-Schmidt K.U., and Inhoffen W. Retinal pigment epithelial tears after single administration of intravitreal bevacizumab for neovascular age-related macular degeneration. Eye 23 (2009) 694-702
15. Honda S., Hirabayashi H., Tsukahara Y., and Negi A. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 246 (2008) 1061-1063
16. Ameri H., Chader G.J., Kim J.G., Sadda S.R., Rao N.A., and Humayun M.S. The effects of intravitreous bevacizumab on retinal neovascular membrane and normal capillaries in rabbits. Invest Ophthalmol Vis Sci. 48 (2007) 5708-5715
17. Dib E., Maia M., Longo-Maugeri I.M., Martins M.C., Mussalem J.S., Squaiella C.C., Penha F.M., Magalhães Jr. O., Rodrigues E.B., and Farah M.E. Subretinal bevacizumab detection after intravitreous injection in rabbits. Invest Ophthalmol Vis Sci 49 (2008) 1097-1100
18. Horn W., and Hoerauf H. Intravitreal injections during anticoagulant treatment. Klin Monatsbl Augenheilkd 225 (2008) 217-219
19. Dayani P.N., Siddiqi O.K., and Holekamp N.M. Safety of intravitreal injections in patients receiving warfarin anticoagulation. Am J Ophthalmol 144 (2007) 451-453
20. Tilanus M.A., Vaandrager W., Cuypers M.H., Verbeek A.M., and Hoyng C.B. Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 238 (2000) 482-485
21. Iguchi Y., Ito Y., Kikuchi M., Ishikawa K., Oshima H., Yatsuya H., and Terasaki H. Seasonal variations of acute massive submacular haemorrhage associated with age-related macular degeneration. Br J Ophthalmol 90 (2006) 1256-1258
22. Nicolò M., Ghiglione D., Lai S., and Calabria G. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol 15 (2005) 415-419
23. Frimpong-Boateng A., Varde M.A., Rüfer F., Bunse A., and Roider J. Intravitreal administration of triamcinolone and bevacizumab for pigment epithelial detachment in conjunction with AMD. Ophthalmologe 105 (2008) 661-668